Everolimus (RAD-001) is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).It is currently used as an immunosuppressant to prevent rejection of organ transplants and treatment of renal cell cancer and other tumours.
This page contains content from the copyrighted Wikipedia article "Everolimus"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
